Bio-Me has raised NOK 10 million in a fully subscribed funding round.
Both existing and new investors participated in the financing round, with new investors contributing the majority of the capital, states the company in a press release.
“We are excited to move forward with our plans to achieve specific value-driving milestones that position PMP as the preferred solution for therapeutic microbiome companies.”
“The successful funding round is an important step towards positioning Bio-Me for further growth and being a leader in microbiome-based Precision Medicine. We are excited to move forward with our plans to achieve specific value-driving milestones that position PMP as the preferred solution for therapeutic microbiome companies,” says Morten Isaksen, CEO of Bio-Me.
The funding round makes it possible for the company to further progress several of its clinical programs and explore other business opportunities for shorter-term revenue generation.
Precision Microbiome Profiling
Bio-Me has developed a novel gut microbiome analysis tool in collaboration with Thermo Fisher Scientific, called Precision Microbiome Profiling (PMP). PMP offers a targeted approach to microbiome analysis/profiling using qPCR technology. It enables the analysis of 100 – 200 samples in 2 hours according to the company. The technology allows Bio-Me to deliver a test that has the potential to meet the requirements for clinical diagnostic applications.
Photo of Morten Isaksen: Bio-Me